| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,017 | 0,020 | 21.11. |
| Zeit | Aktuelle Nachrichten
Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | Genflow Biosciences - Total Voting Rights | - | RNS | ||
| 09.10. | Genflow Biosciences PLC Announces Corporate Update | 479 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 09.10. | Genflow Biosciences - Corporate Update | 4 | RNS | ||
| 05.10. | Genflow Biosciences PLC Announces Presentation of Interim Results | 306 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.10. | Genflow Biosciences - Presentation of Interim Results | 1 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.09. | Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity | 450 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 29.09. | Genflow Biosciences - Exercise of Warrants and Issue of Equity | 2 | RNS | ||
| 29.09. | Genflow Biosciences GAAP EPS of -£0.08 | 3 | Seeking Alpha | ||
| 29.09. | Genflow Biosciences PLC Announces Half-year Financial Report | 336 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 29.09. | Genflow Biosciences - Half-year Financial Report | 1 | RNS | ||
| 08.09. | Genflow Biosciences reports positive anti-ageing dog trial results | 1 | Alliance News | ||
| 08.09. | Genflow: Gentherapie-Studie an Hunden erreicht primären Endpunkt | 2 | Investing.com Deutsch | ||
| 08.09. | Genflow meets primary endpoint in aged dog gene therapy trial | 2 | Investing.com | ||
| 08.09. | Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met | 391 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 08.09. | Genflow Biosciences - Primary Endpoint in SLAB Clinical Trial Met | 1 | RNS | ||
| 07.09. | Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser | 289 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces... ► Artikel lesen | |
| 07.09. | Genflow Biosciences - Appointment of Investor Relations Adviser | - | RNS | ||
| 03.08. | Genflow Biosciences PLC Announces Patent Update | 329 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 03.08. | Genflow Biosciences - Patent Update | 1 | RNS | ||
| 13.07. | Genflow meldet positive Studiendaten bei Hunden und sichert sich LNP-Partnerschaft | 1 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 35,735 | +0,07 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,500 | -0,03 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| DENALI THERAPEUTICS | 16,140 | -4,01 % | Denali Therapeutics auf der Jefferies Global Healthcare Conference: Starker Produktstart stützt Pipeline-Ambitionen | ||
| VOYAGER THERAPEUTICS | 1,456 | +4,67 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| BIOAGE LABS | 3,930 | +0,56 % | BioAge Labs richtet BGE-102 neu aus: Fokus auf Augenerkrankungen statt Kardiologie | ||
| LINEAGE CELL THERAPEUTICS | 0,763 | +6,71 % | Roche treibt neue Stammzelltherapie gegen Erblindung voran - Mesoblast meldet Fortschritte bei US-Vermarktung | ||
| BIOPHYTIS | 0,027 | 0,00 % | XFRA 6XB3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SERINA THERAPEUTICS | 1,060 | -11,67 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 | - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data - - Pharmacokinetic observations at the lowest dose... ► Artikel lesen | |
| LONGEVERON | 1,670 | +0,60 % | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 45,070 | -0,40 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,900 | 0,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 300,67 | +0,08 % | Praxis Precision Medicines: B.Riley initiiert Coverage mit "Buy" - Zulassungsentscheidungen rücken näher | ||
| DYNE THERAPEUTICS | 15,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 13,600 | -0,07 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| CG ONCOLOGY | 79,58 | +0,14 % | Guggenheim raises CG Oncology stock price target on trial results |